Genetically determined debrisoquine oxidation capacity in bladder cancer.

A report is given of a series of bladder cancer cases examined for the oxidation capacity demonstrated by the use of debrisoquine. No overall association of poor and extensive metaboliser exists between bladder cancer patients and a control group. An absolute association between a benzidine exposed subgroup and metaboliser status exists, but the numbers are too small to indicate the true nature of this relationship.